Portal Biotechnologies closes oversubscribed $9M seed led by NFX
What's the deal? Portal BiotechnologiesDealroom has a profile for this one. Try Dealroom →, a Watertown, Massachusetts-based cell engineering and drug discovery platform company, has closed an oversubscribed $9M seed round led by NFX. Existing investors IA Ventures, Pear VC, Undeterred Ventures, IKJ CapitalDealroom has a profile for this one. Try Dealroom →, and TechU Ventures also participated.
The company builds what it calls "universal infrastructure for cell engineering" — a proprietary mechanoporation platform that delivers RNA, gene editors, probes, and other molecules into hard-to-transfect cells without compromising their function. It operates at more than 100 customer sites, including the top 10 pharma companies.
Why now? Portal has hit several milestones that make the timing ripe for scaling. Researchers at Merck, AbbVieDealroom has a profile for this one. Try Dealroom →, and PurdueDealroom has a profile for this one. Try Dealroom → have presented novel applications using its technology. Multiple pharma customers have upgraded to its high-throughput Galaxy-i platform since it launched earlier this year.
DARPADealroom has a profile for this one. Try Dealroom → expanded an initial $8M contract with Portal to develop a portable, field-deployable device for rapid point-of-care cell therapy production. The Ragon Institute of Harvard/MIT/MGB and Microsoft have committed to a two-year project using Portal to generate model training data and map immune responses at scale.
"Portal is achieving what very few biotech platforms manage in their first three years: meaningful commercial revenue, technical validation from the world's largest companies, and a genuinely game-changing vision," said Omri Amirav-Drory, general partner at NFX Bio.
What could go wrong? The cell engineering space is competitive, with established methods like viral vectors and electroporation deeply embedded in pharma workflows. Convincing large organisations to switch platforms — even superior ones — takes time and resources that a $9M seed round may strain.
Portal also faces the classic platform-company risk: it needs to prove its technology works reliably across many cell types and applications, not just in controlled demonstrations.
The signal: NFX, best known for backing network-effect-driven software companies, leading a biotech seed round underscores how investor appetite is shifting toward platform infrastructure plays in the life sciences. Portal's classification as a "breakout stage" company — already generating revenue and operating at more than 100 customer sites — is unusual for a $9M seed and suggests the round was priced to accelerate commercialisation rather than fund early R&D. The DARPA contract expansion and Microsoft collaboration further de-risk the bet, giving Portal non-dilutive capital and blue-chip validation that most seed-stage biotechs lack.
Read more: streetinsider.com
